SIGYOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Sigyn Therapeutics, Inc.
Financials through Q3 FY2025, quarter ended Sep 30, 2025Last filing: 10-Q on Nov 14, 2025
$0.03+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $48.16K
- P/E (TTM)
- –
- Dividend yield
- –
Sigyn Therapeutics, Inc. revenue by segment
By business segment
| Revenue | Q3 20 | Q2 20 | Q1 20 | Q4 19 | Q3 19 | Q2 19 | Q1 19 | Q4 18 | Q3 18 | Q2 18 | Q1 18 | Q4 17 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wholesale Sales [Member] | $3.83K | $0 | $756 | $5.34K | $32.10K | $756 | $41.55K | $6.67K | $1.99K | $23.42K | $55.61K | $39.69K | 100.0% | -88.1% |
| Retail sales [Member] | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $162.35K | $88.46K | $153.51K | $217.64K | $283.99K | 0.0% | – |
By product or service
By region
From the segment and revenue-disaggregation notes of Sigyn Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.